MedTrace Logo

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

NCT07053358 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-03-10

No results posted yet for this study

Summary

The goal of this study is to evaluate the safety and efficacy of LX111 treatment of nAMD. This study will enroll subjects aged ≥ 50 vears old to receive a single unilateral intravitreal (lVT) injection of LX111 to evaluate its safety and efficacy.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

GENETIC

LX111 Injection

Qualified subjects will receive a single unilateral intravitreal injection of LX111 at Day 0.

Sponsors & Collaborators

  • Innostellar Biotherapeutics Co.,Ltd

    collaborator INDUSTRY

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-02
Primary Completion
2026-11-23
Completion
2029-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07053358 on ClinicalTrials.gov